7. CONCLUSION It is becoming quite clear that the etiology of human breast cancer is exceedingly complex, with probable multiple factors involved in its etiology. Molecular epidemiology and the use of markers of susceptibility, internal dose, and early effects may elucidate not only mechanisms, but also clarify relationships between risk factors and disease among subsets of the population who are specifically at risk. For the public, however, lifestyle modification to maintain normal weight, eat a diet high in fruits and vegetables, and refraining from tobacco use and alcohol consumption, should be advised for all women, regardless of genetic makeup.
1. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995; 87:1681-1685.
2. Russo J, Russo IH. Biological and molecular bases of mammary carcinogenesis. Lab Invest 1987; 57:112-37.
3. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995; 4:567-571.
4. Marcus PM, Newman B, Moorman PG, Millikan RC, Baird DD, Qaqish B, et al. Physical activity at age 12 and adult breast cancer risk (United States). Cancer Causes Control 1999; 10:293-302.
5. Marcus PM, Newman B, Millikan RC, Moorman PG, Baird DD, Qaqish B. The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States). Cancer Causes Control 2000; 11:271-278.
6. Janerich DT, Hoff MB. Evidence for a crossover in breast cancer risk factors. Am J Epidemiol 1982; 116:737-742.
7. Lubin F, Ruder AM, Wax Y, Modan B. Overweight and changes in weight throughout adult life in breast cancer etiology. A case-control study. Am J Epidemiol 1985; 122:579-588.
8. Velentgas P, Daling JR. Risk factors for breast cancer in younger women. J Natl Cancer Inst Monogr 1994; 15-24.
9. Hislop TG, Coldman AJ, Elwood JM, Brauer G, Kan L. Childhood and recent eating patterns and risk of breast cancer. Cancer Detect Prev 1986; 9:47-58.
10. Hunter DJ, Willett WC. Diet, body size, and breast cancer. [Review]. Epidemiol Rev 1993; 15:110-132.
11. Sellers TA, Kushi LH, Potter JD, Kaye SA, Nelson CL, McGovern PG, et al. Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med 1992; 326:1323-1329.
12. Sellers TA, Potter JD, Severson RK, Bostick RM, Nelson CL, Kushi LH, et al. Difficulty becoming pregnant and family history as interactive risk factors for postmenopausal breast cancer: the Iowa Women’s Health Study. Cancer Causes Control 1993; 4:21-28.
13. Tutera AM, Sellers TA, Potter JD, Drinkard CR, Wiesner GL, Folsom AR. Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status. Genet Epidemiol 1996; 13:207-221.
14. Sellers TA, Minks T, Cerhan JR, Zheng W, Anderson KE, Kushi LH, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127:973-980.
15. Andrieu N, Duffy SW, Rohan TE, Le MG, Luporsi E, Renaud R, et al. Familial risk, abortion and their interactive effect on the risk of breast cancer-a combined analysis of six case-control studies. Br J Cancer 1995; 72:744-751.
16. Ambrosone CB, Marshall JR, Vena JE, Laughlin R, Graham S, Nemoto T, et al. Interaction of family history of breast cancer and dietary antioxidants with breast cancer risk (New York, United States). Cancer Causes Control 1995; 6:407-415.
17. Brinton LA, Hoover R, Fraumeni JF Jr. Interaction of familial and hormonal risk factors for breast cancer. J Natl Cancer Inst 1982; 69:817-822.
18. Byrne C, Brinton LA, Haile RW, Schairer C. Heterogeneity of the effect of family history on breast cancer risk. Epidemiology 1991; 2:276-284.
19. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 1987; 125:769-779.
20. Parazzini F, La Vecchia C, Negri E, Franceschi S, Bocciolone L. Menstrual and reproductive factors and breast cancer in women with family history of the disease. Int J Cancer 1992; 51:677-681.
21. Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996; 88:365-371.
22. Egan KM, Stampfer MJ, Rosner BA, Trichopoulos D, Newcomb PA, Mittendorf R, et al. Risk factors for breast cancer in women with a breast cancer family history. Cancer Epidemiol Biomarkers Prev 1998; 7:359-364.
23. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
24. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265:2088-2091.
25. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996; 334:137-142.
26. Narod SA, Goldgar D, Cannon-Albright L, Weber BL, Moslehi R, Ives E, et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995; 64:394-398.
27. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91:1475-1479.
28. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999; 64:1371-1377.
29. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al. Modification of breast cancer risk in BRCA1 mutation carriers by the A1B1 gene. Proc Amer Assoc Cancer Res 1999; 40:194.
30. Menin C, Banna GL, De Salvo G, Lazzarotto V, De Nicolo A, Agata S, et al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 2001; 168:31-36.
31. Given HF, Radbourne R, Oag H, Merritt S, Barclay E, Hanby AM, et al. The androgen receptor exon 1 trinucleotide repeat does not act as a modifier of the age of presentation in breast cancer. Eur J Cancer 2000; 36:533-534.
32. Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, et al. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1 /2 carriers and non-carriers. Br J Cancer 2001; 85:36-40.
33. Spurdle AB, Dite GS, Chen X, Mayne CJ, Southey MC, Batten LE, et al. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst 1999; 91:961-966.
34. Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses’ Health Study. Cancer Res 2002; 62:1045-1049.
35. Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 1998; 90:761-766.
36. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999; 354:1846-1850.
37. Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998; 352:1359-1360.
38. Hunter DJ, Spiegelman D, Adami HO, Beeson L, van den Brandt PA, Folsom AR, et al. Cohort studies of fat intake and the risk of breast cancer-a pooled analysis. N Engl J Med 1996; 334:356-361.
39. Toniolo P, Riboli E, Shore RE, Pasternack BS. Consumption of meat, animal products, protein, and fat and risk of breast cancer: a prospective cohort study in New York [see comments]. Epidemiology 1994; 5:391-397.
40. Missmer SA, Smith-Warner SA, Spiegelman D, Yaun SS, Adami HO, Beeson WL, et al. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol 2002; 31:78-85.
41. Hunter DJ, Willett WC. Nutrition and breast cancer. Cancer Causes Control 1996; 7:56-68.
42. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. J Am Med Assoc 2001; 286:2143-2151.
43. Boyd NF, Martin LJ, Noffel M, Lockwood GA, Tritchler DL. A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer 1993; 68: 627-636.
44. Willett WC. The search for the causes of breast and colon cancer. Nature 1989; 338:389-394.
45. Cave WT. Dietary fat effects on animal models of breast cancer. In: Weisburger EK, ed. Diet and Breast Cancer. New York: Plenum Press, 1994.
46. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975; 15:617-631.
47. Caroll KK, Braden LM, Bell JM, Kalamegham R. Fat and cancer. Cancer 1986; 58:1818-1825.
48. Dunn JE. Breast cancer among American Japanese in the San Francisco bay area. J Natl Cancer Inst Monogr 1975; 47:157-160.
49. Potischman N, Weiss HA, Swanson CA, Coates RJ, Gammon MD, Malone KE, et al. Diet during adolescence and risk of breast cancer among young women. J Natl Cancer Inst 1998; 90:226-233.
50. Ip C. Controversial issues of dietary fat and experimental mammary carcinogenesis. Prev Med 1993; 22:728-737.
51. Goodwin PJ, Boyd NF. Critical appraisal of the evidence that dietary fat intake is related to breast cancer risk in humans. J Natl Cancer Inst 1987; 79: 473-485.
52. Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, et al. Comparison of dietary assessment methods in nutritional epidemiology: weighted records v. 24h recalls, food frequency questionnaires and estimated diet records. Br J Nutr 1994; 72:643.
53. Beisiegel U, Weber W, Ihrke G. The LDL-receptor related protein, LPR, is an apolipoprotein E binding protein. Nature 1989; 341:162-170.
54. Uterman G. Apoliproprotein E polymorphism in health and disease. Am Heart J 1987; 113:433-440.
55. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8:1-21.
56. Kuusisto J, Koivisto K, Kervinen K, Mykkanen L, Helkala EL, Vanhanen M, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer’s disease: population based study. Br Med J 1994; 309:636-638.
57. Kervinen K, Savolainen MJ, Salokannel J, Hynninen A, Heikkinen J, Ehnholm C, et al. Apolipoprotein E and B polymorphisms-longevity factors assessed in nonagenarians. Atherosclerosis 1994; 105:89-95.
58. Bowman ED, Broemke B, Lensing W, Shields PG. Apolipoprotein E allelic frequency in elderly smokers. Am J Med Genet 1998; 76:32-36.
59. Moysich KB, Freudenheim JL, Baker JA, Ambrosone CB, Schisterman EF, Vena JE, Shields PG. Apolipoprotein E polymorphism, cholesterol, and breast cancer risk. Mol Carcinog 2000; 27:2-9.
60. Ronco A, Destefani E, Mendilaharsu M, Deneopellegrini H. Meat, fat and risk of breast cancer-a case-control study from Uruguay. Int J Cancer 1996; 65:328-331.
61. Destefani E, Ronco A, Mendilaharsu M, Guidobono M, Deneo-Pellegrini H. Meat intake, heterocyclic amines, and risk of breast cancer: a case-control study in Uruguay. Cancer Epidemiol Biomarkers Prev 2001; 6:573-581.
62. Snyderwine EG. Some perspectives on the nutritional aspects of breast cancer research. Food-derived heterocyclic amines as etiologic agents in human mammary cancer. [Review]. Cancer 1994; 74:1070-1077.
63. Felton JS, Knize MG, Salmon CP, Malfatti MA, Kulp KS. Human exposure to heterocyclic amine food mutagens/carcinogens: relevance to breast cancer. Environ Mol Mutagen 2002; 39:112-118.
64. DeBruin LS, Martos PA, Josephy PD. Detection of PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) in the milk of healthy women. Chem Res Toxicol 2001; 14:1523-1528.
65. Gorlewska-Roberts K, Green B, Fares M, Ambrosone CB, Kadlubar FF. Carcinogen-DNA adducts in human breast epithelial cells. Environ Mol Mutagen 2002; 39:184-192.
66. Thompson PA, DeMarini DM, Kadlubar FF, McClure GY, Brooks LR, Green BL, et al. Evidence for the presence of mutagenic arylamines in human breast milk and DNA adducts in exfoliated breast ductal epithelial cells. Environ Mol Mutagen 2002; 39:134-142.
67. Lang NP, Butler MA, Massengill J, Lawson M, Stotts C, Kadlubar FF. Aromatic amine metabolism and diet in colorectal cancer polyp and cancer patients. International Conference on Environment Mutations, Satellite Meeting, Auckland, New Zealand, 1993.
68. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-1692.
69. Cartwright RA. Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia. In: Omenn GS, Gelboin HV, eds. Genetic variability in Responses to Chemical Exposure. Cold Spring Harbor, NY: : Cold Spring Harbor Press, 1984:359-368.
70. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. J Am Med Assoc 1996; 276:1494-1501.
71. Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acet-ylator status, smoking, diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997; 18:1351-1354.
72. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994; 3:675-682.
73. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, et al. Combined effects of well-done red meat, smoking, and rapid N-acetyl-transferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:1259-1266.
74. Debiec-Rychter M, Land SJ, King CM. Tissue-specific expression of human acetyltransferase 1 and 2 detected by non-isotopic in situ hybridization (Abstract). Proc Am Assoc Cancer Res 1996; 37:133.
75. Sadrieh N, Davis CD, Snyderwine EG. N-Acetyltransferase expression and metabolic activation of their food-derived heterocyclic amines in the human mammary gland. Cancer Res 1996; 56:2683-2687.
76. Dubuisson JG, Gaubatz JW. Bioactivation of the proximal food mutagen 2-hydroxyamino-1-methyl-6-phenylimidazo [4,5-b]pyridine (N-OH-PhIP) to DNA-binding species by human mammary gland enzymes. Nutrition 1998; 14:683-686.
77. Ambrosone CB, Freudenheim JL, Sinha R, Graham S, Marshall JR, Vena JE, et al. Breast cancer risk, meat consumption and N-acetyltransferase (NAT2) genetic polymorphisms. Int J Cancer 1998; 75:825-830.
78. Zheng W, Gustafson DR, Sinha R, Cerhan JR, Moore D, Hong C-P, et al. Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst 1998; 90:1724-1729.
79. Delfino RJ, Sinha R, Smith C, West J, White E, Lin HJ, et al. Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. Carcinogenesis 2000; 21:607-615.
80. Deitz AC, Zheng W, Leff MA, Gross M, Wen WQ, Doll MA, et al. N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000; 9:905-910.
81. Gertig DM, Hankinson SE, Hough H, Spiegelman D, Colditz GA, Willett WC, et al. N-Acetyltransferase 2 genotypes, meat intake and breast cancer risk. Int J Cancer 1999; 80:13-17.
82. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996; 96:1027-1039.
83. Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, et al. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst 1999; 91:547-556.
84. Byers T. Nutritional risk factors for breast cancer. Cancer 1994; 74:288-295.
85. Smith-Warner SA, Spiegelman D, Yaun SS, Adami HO, Beeson WL, van den Brandt PA, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. J Am Med Assoc 2001; 285:769-776.
86. Graham S, Zielezny M, Marshall J, Priore R, Freudenheim J, Brasure J, et al. Diet in the epidemiology of postmenopausal breast cancer in the New York State Cohort [see comments]. Am J Epidemiol 1992; 136:1327-1337.
87. Graham S, Hellmann R, Marshall J, Freudenheim J, Vena J, Swanson M, et al. Nutritional epidemiology of postmenopausal breast cancer in western New York [see comments]. Am J Epidemiol 1991; 134:552-566.
88. Freudenheim JL, Marshall JR, Vena JE, Laughlin R, Brasure JR, Swanson M, et al. Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. J Natl Cancer Inst 1996; 88:340-348.
89. Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000; 2:903-917.
90. Oberly TD, Oberly LW. Antioxidant enzyme levels in cancer. Histol Histo-pathol 1997; 12:525-535.
91. Schwartz JL, Antoniades DZ, Zhao S. Molecular and biochemical reprogramming of oncogenesis through the activity of prooxidants and antioxidants. Ann N Y Acad Sci 1993; 686:262-278.
92. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Oxford University Press, 1989.
93. Cerutti PA. Oxy-radicals and cancer. Lancet 1994; 344:862-863.
94. Emerit I. Reactive oxygen species, chromosome mutation and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med 1994; 16: 99-109.
95. Esterbauer H, Jurgens G. Mechanistic and genetic aspects of susceptibility of LDL to oxidation. Curr Opin Lipidol 1993; 4:114-124.
96. Halliwell B. Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am J Clin Nutr 2000; 72: 1082-1087.
97. Musarrat J, Arezina-Wilson J, Wani AA. Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer 1996; 32A:1209-1214.
98. Djuric Z, Heilbrun L, Simon MS, Smith D, Luongo DA, LoRusso PM, et al. Levels of 5-hydroxymethyl-2'-deoxyuridine in DNA from blood as a marker of breast cancer. Cancer 1996; 77:696.
99. Li D, Zhang W, Zhu J, Chang P, Sahin A, Singletary E, et al. Oxidative DNA damage and 8-hydroxy-2-deoxyguanosine DNA glycosylase/apurinic lyase in human breast cancer. Mol Carcinog 2001; 31:214-223.
100. Djuric Z, Depper JB, Uhley V, Smith D, Lababidi S, Martino S, et al. Oxidative DNA damage levels in blood from women at high risk for breast cancer are associated with dietary intakes of meats, vegetables, and fruits. J Am Diet Assoc 1998; 98:524-528.
101. Rehman A, Bourne LC, Halliwell B, Rice-Evans CA. Tomato consumption modulates oxidative DNA damage in humans. Biochem Biophys Res Commun 1999; 262:828-831.
102. Verhagen H, Poulsen HE, Loft S, van Poppel G, Willems MI, van Bladeren PJ. Reduction of oxidative DNA-damage in humans by brussels sprouts. Carcinogenesis 1995; 16:969-970.
103. Wispe JR, Clark JC, Burhans MS, Dropp KE, Korfhagen TR, Whitsett JA. Synthesis and processing of the precursor for human mangano-superoxide dis-mutase. Biochim Biophys Acta 1989; 994:30-36.
104. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson’s disease. Biochem Biophys Res Commun 1996; 226:561-565.
105. Rohrdanz E, Kahl R. Alterations of antioxidant enzyme expression in response to hydrogen peroxide. Free Rad Biol Med 1998; 24:27-38.
106. Gilks CB, Price K, Wright JL, Churg A. Antioxidant gene expression in rat lung after exposure to cigarette smoke. Am J Pathol 1998; 152:269-278.
107. Rosenblum JS, Gilula NB, Lerner RA. On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci 1996; 93:4471-4473.
108. Ambrosone CB, Freudenheim JL, Thompson PA, Bowman ED, Vena JE, Marshall JR, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants and risk of breast cancer. Cancer Res 1999; 59:602-606.
109. Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma V-M, Benhamou S, et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 2001; 22:827-829.
110. Schatzkin A, Longnecker MP. Alcohol and breast cancer. Cancer 1994; 74:1101-1110.
111. Longnecker MP. Alcoholic beverage consumption in relation to breast cancer risk: meta-analysis and review. Cancer Causes Control 1994; 5:73-82.
112. Ginsburg ES, Mello NK, Mendelson JH, Barbieri RL, Teoh SK, Rothman M, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. J Am Med Assoc 1996; 276:1747-1751.
113. Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, et al. The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women. Cancer Causes Control 1994; 5:53-60.
114. Bosron WF, Li TK. Genetic polymorphisms of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology 1986; 6:502-510.
115. Harty LC, Caporaso NE, Hayes RB, Winn DM, Bravo-Otero E, Blot WJ, et al. Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst 1997; 89:1698-1705.
116. Coutelle C, Ward PJ, Fleury B, Quattrocchi P, Chambrin H, Iron A, et al. Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum Genet 1997; 99:319-325.
117. Bashir R, James OFW, Bassendine MF, Crabb DW, Thomasson HR, Li TK, et al. Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage. Hepatology 1991; 6:502-510.
118. Freudenheim JL, Ambrosone CB, Moysich KB, Vena JE, Graham S, Marshall JR, et al. Alcohol dehydrogenase 3 genotype and risk of breast cancer associated with alcohol consumption. Cancer Causes Control 1999; 10: 369-377.
119. Visvanathan K, Bell DA, Strickland PT, Alberg AJ, Hoffman S, Helzlsouer KJ. Association of ADH3, GSTM1 and alcohol and the risk of breast cancer. Proc Amer Assoc Cancer Res 1999; 40:194.
120. Hines LM, Hankinson SE, Smith-Warner SA, Spiegelman D, Kelsey KT, Col-ditz GA, et al. A prospective study of the effect of alcohol consumption and ADH3 genotype on plasma steroid hormone levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9:1099-1105.
121. Hu Y, Oscarson M, Johansson I, Yue Q-Y, Dahl M-L, Tabone M, et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51:370-376.
122. Shields PG, Ambrosone CB, Graham S, Bowman ED, Harrington A, Gillenwater K, et al. A cytochrome P4502E1 genetic polymorphism and tobacco smoking in breast cancer. Molec Carc 1996; 17:144-150.
123. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. [Review]. Epidemiol Rev 1993; 15:17-35.
124. Dorgan JF, Longcope C, Stephenson HE, Falk RT, Miller R, Franz C, et al. Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect 1997; 105:583-585.
125. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998; 58:65-70.
126. Rebbeck TR, Rosvold EA, Duggan DJ, Zhang J, Buetow KH. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol Biomarkers Prev 1994; 3:511-514.
127. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995; 55:3483-3485.
128. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995; 55:3757-3758.
129. Ishibe N, Hankinson SE, Colditz GA, Spiegelman DL, Willett WC, Speizer FE, et al. Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer risk in the Nurses’ Health Study. Cancer Res 1998; 58:667-671.
130. Basham VM, Pharoah PD, Healey CS, Luben RN, Day NE, Easton DF, et al. Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk. Carcinogenesis 2001; 22:1797-1800.
131. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997; 57:1063-1065.
132. Dunning AM, Healey CS, Pharoah PDP, foster NA, Lipscombe JM, Redman KL, et al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 1998; 77:2045-2047.
133. Helzlsouer KJ, Huang H-Y, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, et al. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:945-949.
134. Weston A, Pan C-F, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, et al. CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7:941-944.
135. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, et al. Relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999; 59:1015-1020.
136. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma V-M, Benhamou S, et al. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9:1343-1348.
137. Lai J, Vesprini D, Chu W, Jernstrom H, Narod SA. CYP gene polymorphisms and early menarche. Mol Genet Metab 2001; 74:449-457.
138. Ye Z, Parry JM. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002; 17:119-126.
139. Sasano H, Nagura H, Harada N, Goukon Y, Kimura M. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 1994; 25:535.
140. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998; 8:43-48.
141. Siegelmann-Danieli N, McGlynn KA, Buetow KH. Human aromatase as a candidate for breast cancer susceptibility. Am J Hum Genetics 1996; 59:A82.
142. Baxter SW, Choong DY, Eccles DM, Campbell IG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001; 22:347-349.
143. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:215-216.
144. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27:135-206.
145. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, et al. Molecular origin of cancer: catechol estrogen-3-4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997; 94: 10937-10942.
146. Lavigne JA, Helzlsouer KJ, Huang H-Y, Strickland PT, Bell DA, Selmin O, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997; 57:5493-5497.
147. Thompson PA, Shields PG, Freudenheim JL, Stone AA, Vena JE, Marshall JR, et al. Genetic polymorphisms in catechol-O-methyltransferase (COMT), menopausal status and breast cancer risk. Cancer Res 1998; 58:2107-2110.
148. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:635-640.
149. Yim DS, Parkb SK, Yoo KY, Yoon KS, Chung HH, Kang HL, et al. Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 2001; 11:279-286.
150. Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, et al. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 1998; 19: 1943-1947.
151. Bergman-Jungestrom M, Wingren S. Catechol-O-methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. Br J Cancer 2001; 85:859-862.
152. American Cancer Society. Cancer Facts and Figures-1999. Atlanta, GA: American Cancer Society, Inc., 1999.
153. Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. [Review]. Epidemiol Rev 1993; 15:7-16.
154. International Agency for Research on Cancer. DDT and associated compounds. IARC Monogr 1992; 53:179-249.
155. Safe S, Bandiera SM, Sawyer T, Robertson L, Safe L, Parkinson A, et al. PCBs: structure-function relationships and mechanism of action. Environ Health Perspect 1985; 60:47-56.
156. Bulger WH, Kupfer D. Polychlorinated biphenyls as hormonally active structural analogues. Environ Health Perspect 1994; 102:290-294.
157. McKinney JD, Waller CD. Polychlorinated biphenyls as hormonally active structural analogues. Environ Health Perspect 1994; 102:290-297.
158. Jansen HT, Cooke PS, Poecelli J, Liu TC, Hansen LG. Estrogenic and antiestrogenic actions of PCBs in the female rat: in vitro and in vivo studies. Reprod Toxicol 1993; 7:237-241.
159. Banerjee BD. Effects of sub-chronic DDT exposure on humoral and cell-mediated immune responses in albino rats. Bull Environ Contam Toxicol 1987; 39:827-834.
160. Kimbrough RD. Laboratory and human studies on polychlorinated biphenyls (PCBs) and related compounds. Environ Health Perspect 1985; 59:99-106.
161. Norback DH, Weltman RH. Polychlorinated biphenyl induction of hepatoel-lular carcinoma in the Sprague-Dawley rat. Environ Health Perspect 1985; 60:97-105.
162. Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organo-chlorine residues and risk of breast cancer. J Natl Cancer Inst 1993; 85: 648-652.
163. Moysich KB, Ambrosone CB, Vena J, Mendola P, Marshall JR, Graham S, et al. Environmental organochlorine exposure and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7:181-188.
164. Hunter DJ, Hankinson SE, Laden F, Colditz GA, Manson JE, Willett WC, et al. Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 1997; 337:1253-1258.
165. Helzlsouer KJ, Alberg AJ, Huang H-Y, Hoffman SC, Strickland PT, Brock JW, et al. Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:525-532.
166. Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelman JH, Orentreich N. Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. J Natl Cancer Inst 1994; 86:589-599.
167. Olaya-Contreras P, Rodriguez-Villamil J, Posso-Valencia HJ, Cortez JE. Organochlorine exposure and breast cancer risk in Colombian women. Cader-nos de Saude Publica 1998; 14S:125-132.
168. Lopez-Carrillo L, Blair A, Lopez-Cervantes M, Cebrian M, Rueda C, Reyes R, et al. Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Cancer Res 1997; 57:3728-3732.
169. Schecter A, Toniolo P, Dai LC, Thuy LT, Wolff MS. Blood levels of DDT and breast cancer risk among women living in the North of Vietnam. Arch Environ Contam Toxicol 1997; 33:453-456.
170. Hoyer AP, Grandjean P, Jorgensen T, Brock JW, Hartvig HB. Organochlor-ine exposure and risk of breast cancer. Lancet 1998; 352:1816-1820.
171. Guttes S, Failing K, Neumann K, Kleinstein J, Georgii S, Brunn H. Chloror-ganic pesticides and polychlorinated biphenyls in breast tissue of women with benign and malignant breast disease. Arch Environ Contam Toxicol 1998; 35:140-147.
172. Van’t Veer P, Lobbezoo IE, Martin-Moreno JM, Guallar E, Gomez-Aracena J, et al. DDT (dicophane) and postmenopausal breast cancer in Europe: case-control study. Br Med J 1997; 315:81-85.
173. Wolff M, Berkowitz G, Brower S, Senie R, Bleiweiss I, Tartter P, et al. Orga-nochlorine exposures and breast cancer risk in New York City Women. Environ Res 2000; 84:151-161.
174. Millikan R, DeVoto E, Duell EJ, Tse CK, Savitz DA, Beach J, et al. Dichlor-odiphenyldichloroethene, polychlorinated biphenyls, and breast cancer among African-American and white women in North Carolina. Cancer Epidemiol Biomarkers Prev 2000; 9:1233-1240.
175. Laden F, Collman G, Iwamoto K, Alberg AJ, Berkowitz GS, Freudenheim JL, et al. 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst 2001; 93:768-776.
176. Moysich KB, Ambrosone CB, Mendola P, Kostyniak PJ, Greizerstein HB, Vena JE, et al. Exposures associated with serum organochlorine levels among postmenopausal women from western New York State. Am J Ind Med 2002; 41:102-110.
177. Moysich KB, Shields PG, Freudenheim J, Vena JE, Kotake T, Grenberg-Funes RA, et al. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:41-44.
178. Drahushuk AT, Choy CO, Kumar S, McReynolds JH, Olson JR. Modulation of cytochrome P450 by 5,5'-bis-triflouromethyl-2,2'-dicholrobiphenyl, a unique environmental comtaminant. Toxicology 1997; 120:197-205.
179. Bandiera SM, Torok SM, Letcher RJ, Norstrom RJ. Immunoquantification of cytochromes P450 1A and P450 2B and comparison with chlorinated hydrocarbon levels in archived polar bear liver samples. Chemosphere 1997; 34:1469-1479.
180. Swaminathan S, Frederickson SM, Hatcher JF. Metabolic activation of N-hydroxy-4-acetylaminobiphenyl by cultured human breast epithelial cell line MCF 10A. Carcinogenesis 1994; 15:611-617.
181. Wang CY, Yamada H, Morton KC, Zukowski K, Lee MS, King CM. Induction of repair synthesis of DNA in mammary and urinary bladder epithelial cells by N-hydroxy derivatives of carcinogenic arylamines. Cancer Res 1988; 48:4227-4232.
182. Allaben WT, Weis CC, Fullerton NF, Beland FA. Formation and persistence of DNA adducts from the carcinogen N-hydroxy-2-acetylaminofluorene in rat mammary gland in vivo. Carcinogenesis 1983; 4:1067-1070.
183. Tonelli QJ, Custer RP, Sorof S. Transformation of cultured mouse mammary glands by aromatic amines and amides and their derivatives. Cancer Res 1979; 39:1784-1792.
184. Shirai T, Fysh JM, Lee MS, Vaught JB, King CM. Relationship of metabolic activation of N-hydroxy-N-acylarylamines to biological response in the liver and mammary gland of the female CD rat. Cancer Res 1981; 41:4346-4353.
185. International Agency for Research on Cancer. Monographs on the evaluation of the Carcinogenic Risk of Chemicals to Humans. 1972; 1:74-79.
186. Cavalieri E, Rogan E, Sinha D. Carcinogenicity of aromatic hydrocarbons directly applied to rat mammary gland. J Cancer Res Clin Oncol 1988; 114:3-9.
187. Chatterjee M, Banerjee MR. Selenium mediated dose-inhibition of 7,12-dimethylbenz[a] anthracene-induced transformation of mammary cells in organ culture. Cancer Lett 1982; 17:187-195.
188. Calaf G, Russo J. Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 1993; 14:483-492.
189. Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol 2001; 11:353-360.
190. Biggs PJ, Warren W, Venitt S, Stratton MR. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. [Review]. Mutagenesis 1993; 8:275-283.
191. Obana H, Hori S, Kashimoto T, Kunita N. Polycyclic aromatic hydrocarbons in human fat and liver. Bull Environ Contam Toxicol 1981; 27:23-27.
192. Martin FL, Carmichael PL, Crofton-Sleigh C, Venitt S, Phillips DH, Grover PL. Genotoxicity of human mammary lipid. Cancer Res 1996; 56:5342-5346.
193. Petrakis NL, Gruenke LD, Beelen TC, Castagnoli N Jr, Craig JC. Nicotine in breast fluid of nonlactating women. Science 1978; 199:303-305.
194. Martin FL, Venitt S, Carmichael PL, Crofton-Sleigh C, Stone EM, Cole KJ, Gusterson BA, Grover PL, Phillips DH. DNA damage in breast epithelial cells: detection by the single-cell gel (comet) assay and induction by human mammary lipid extracts. Carcinogenesis 1997; 18:2299-2305.
195. Ghoshal A, Snyderwine EG. Excretion of food-derived heterocyclic amine carcinogens into breast milk of lactating rats and formation of DNA adducts in the newborn. Carcinogenesis 1993; 14:2199-2203.
196. Perera FP, Estabrook A, Hewer A, Channing K, Rundle A, Mooney LA, et al. Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev 1995; 4:233-238.
197. Li D, Wang M, Dhingra K, Hittelman WN. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res 1996; 56:287-293.
198. Seidman LA, Moore CJ, Gould MN. 32P-postlabeling analysis of DNA adducts in human and rat mammary epithelial cells. Carcinogenesis 1988; 9:1071-1077.
199. Li D, Wang M, Firozi PF, Chang P, Zhang W, Baer-Dubowska W, et al. Characterization of a major aromatic DNA adduct detected in human breast tissues. Environ Mol Mutagen 2002; 39:193-200.
200. Morabia A. Smoking (active and passive) and breast cancer: epidemiologic evidence up to June 2001. Environ Mol Mutagen 2002; 39:89-95.
201. Egan KM, Stampfer MJ, Hunter D, Hankinson S, Rosner BA, Holmes M, et al. Active and passive smoking in breast cancer: prospective results from the Nurses’ Health Study. Epidemiology 2002; 13:138-145.
202. Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. [Review]. Epidemiol Rev 1993; 15:145-156.
203. Wells AJ. Breast cancer, cigarette smoking, and passive smoking [letter]. Am J Epidemiol 1991; 133:208-210.
204. Wells AJ. Breast cancer, cigarette smoking, and passive smoking. The author replies (letter). Am J Epidemiol 1992; 135:710-712.
205. Smith SJ, Deacon JM, Chilvers CE. Alcohol, smoking, passive smoking and caffeine in relation to breast cancer risk in young women. UK National Case Study Group. Br J Cancer 1994; 70:112-119.
206. Lash TL, Aschengrau A. Active and passive cigarette smoking and the occurrence of breast cancer. Am J Epidemiol 1999; 149:5-12.
207. Delfino RJ, Smith C, West JG, Lin HJ, White E, Liao SY, et al. Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 2000; 10:461-469.
208. Morabia A, Bernstein M, Heritier S, Khatchatrian N. Relation of breast cancer with passive and active exposure to tobacco smoke. Am J Epidemiol 1996; 143:918-928.
209. MacMahon B, Trichopoulos D, Cole P, Brown J. Cigarette smoking and urinary estrogens. N Engl J Med 1982; 307:1062-1065.
210. Baron JA. Smoking and estrogen-related disease. [Review]. Am J Epidemiol 1984; 119:9-22.
211. Millikan R, Pittman G, Newman B, Tse C-K, Selmin O, Rockhill B, et al. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7:371-378.
212. Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, et al. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 1997; 18:2127-2132.
213. Ambrosone CB, Coles BF, Freudenheim JL, Shields PG. Glutathione S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants. J Nutr 1999; 129:565S-568S.
214. Garcia-Closas M, Kelsey KT, Hankinson SE, Spigelman D, Springer K, Willett WC, et al. Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst 1999; 91:1960-1964.
215. Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, et al. Glutathione S-transferase m deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev 1997; 6:511-5.
216. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993; 14:1821-1824.
217. Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). Cancer Causes Control 1997; 8:544-553.
218. Helzlsouer KJ, Selmin O, Huang H-Y, Strickland PT, Hoffman S, Alberg AJ, et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 1998; 90:512-518.
219. Garcia-Closas M, Lubin JH. Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches. Am J Epidemiol 1999; 149:689-692.
220. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31:33-36.
221. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001; 61:785-789.
222. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999; 59:4870-4875.